Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Core Insights - Emergent BioSolutions has announced a collaboration with PANTHER to support the Africa CDC-led 'MpOx Study in Africa' (MOSA), aimed at researching treatments for mpox, a virus lacking dedicated antiviral therapy [1] - The MOSA study, launched in 2024, is a double-blind, platform-adaptive clinical trial evaluating treatment options for mpox across multiple African countries, initially funded by the European Union and Africa CDC [1] - An independent data and safety monitoring board (DSMB) reviewed the safety data of MOSA in December 2025, recommending the continuation of the trial with no safety concerns identified [2] Company and Industry Overview - Emergent BioSolutions focuses on protecting public health by delivering life-saving solutions for various health threats, including mpox [5] - PANTHER is an African-led pandemic preparedness platform that aims to enhance regional response to emerging infectious diseases, particularly in Africa [6] - The Africa CDC is a public health agency of the African Union, supporting member states in strengthening health systems and improving disease surveillance and emergency response [8] Study Progress and Impact - The MOSA study represents a significant step in generating evidence for mpox treatment and enhancing Africa's capacity to respond to health threats, with over 61,383 confirmed cases and 296 deaths reported across 32 countries since 2024 [4] - The study will expand to new countries, including Uganda, as part of its efforts to reach the next milestone in patient enrollment [3]